Soley Therapeutics

Executive Summary

Soley Therapeutics is a Cambridge-based biotechnology company pioneering a biology-first drug discovery platform that employs living human cells as biosensors to identify novel small molecule therapies. By integrating advanced imaging, artificial intelligence, and automation, the platform captures whole-cell dynamic responses to disease-relevant perturbations, enabling the targeting of challenging protein-protein interactions in oncology and inflammatory diseases. This approach offers the potential to unlock first-in-class medicines for targets previously considered undruggable. Since its founding in 2016, Soley has operated under the radar, focusing on platform validation and building a proprietary pipeline. While specific financial details and clinical-stage programs are not publicly disclosed, the company's innovative strategy positions it as a potential leader in the next wave of AI-driven drug discovery. The company's near-term outlook hinges on translating its platform into tangible preclinical or clinical candidates. Key upcoming milestones may include the selection of a lead molecule for an oncology or inflammatory disease indication, initiation of IND-enabling studies, or a strategic partnership with a larger pharmaceutical company to co-develop its programs. Given the private nature and early stage, Soley's progress is closely watched by investors interested in platform technologies that can de-risk drug development. Success in demonstrating in vivo proof-of-concept or securing a collaboration would significantly enhance its visibility and valuation.

Upcoming Catalysts (preview)

• Q3 2026Lead Candidate Selection for Oncology Program70% success
• Q4 2026Strategic Partnership or Co-Development Deal50% success
• H2 2026Series B Financing Round80% success